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Abstract. Antibodies directed against malaria parasites are easy and inexpensive to measure but remain an un-
derused surveillance tool because of a lack of consensus on what to measure and how to interpret results. High-
throughput screening of antibodies from well-characterized cohorts offers a means to substantially improve existing
assays by rationally choosing the most informative sets of responses and analytical methods. Recent data suggest that
high-resolution information onmalaria exposure can be obtained from a small number of samples bymeasuring a handful
of properly chosen antibody responses. In this review, we discuss how standardized multi-antibody assays can be
developed and efficiently integrated into existing surveillance activities, with potential to greatly augment the breadth and
quality of information available to direct and monitor malaria control and elimination efforts.
EFFECTIVE MALARIA STRATEGIES REQUIRE GOOD DATA
Elimination of malaria or effective and sustainable control re-
quires deployment of interventions updated using surveillance
data. Contemporary, accurate information on malaria trans-
mission is required to determine which interventions should be
deployed where to reduce transmission effectively given re-
source constraints. Theability to detect changes in transmission
is an integral part of evaluating program activities by providing
evidence for the effectiveness of interventions and identifying
when and where changes are needed. Given the central role of
surveillancedata inguidingstrategy,any tools thatcouldprovide
datamore accurately or cost-effectivelywould be of great value;
the next generation of antibody assays for measuring malaria
transmission holds promise for doing both.
THE CURRENT FOCUS OF MALARIA SURVEILLANCE
Onewould be hard-pressed to find amalaria programofficer,
epidemiologist, or funder of interventions whowould not prefer
a clearer picture of malaria in their target population. Some
types of surveillance data, such as detailed entomological
measurements or cohort studies, are not feasible for routine
surveillance of transmission because they are too resource in-
tensive to be performed extensively. These high-resolution
snapshots are extremely valuable for answering research
questions in small geographic areas at particular times but are
too sparse to provide a contemporary picture of malaria trans-
mission complete enough for programmatic use. The rest of the
picture is filled in primarily from two other sources of data—
routine passive surveillance and cross-sectional surveys. Pas-
sive surveillance data are widely and continuously collected as
health systems provide care to those with malaria. The utility of
these data depend heavily on the quality of diagnosis, com-
pleteness of reporting, and ability to account for important
factors regarding catchment populations, care seeking, and
clinical immunity.1 Thus, although the quality of and access to
these data are improving, limitations remain, particularly in
settings where a small minority of infections get reported
through standard surveillance.2
The most widely collected, standardized data currently
available are basedon surveys that collect blood fromacross-
sectional sample of individuals in a population. The primary
metric collected in most surveys to date has been the preva-
lence of parasites or parasite rate (PR), based on light mi-
croscopy, rapid diagnostic test, or nucleic acid detection (e.g.,
polymerase chain reaction [PCR]). Data from such surveys
form the basis of global maps of malaria.3 Prevalence data,
although useful, are limited in the ability to detect changes in
malaria transmission where transmission is so high that PR
remains high even if exposure decreases considerably, or
where it is so low that infeasibly large sample sizes are re-
quired to accurately measure changes over time or at fine
enough spatial scales to be programmatically useful.4
Prevalencedata are an importantmainstayof surveillance, but
each sample provides a single piece of information—whether a
person has detectable blood-stage infection or not. This is a
particular challenge in seasonal transmission environments or
with Plasmodium vivax, where people can harbor dormant liver-
stage infection without having a concurrent blood-stage in-
fection. It is possible to learn more about malaria exposure from
the same blood sample by additionally measuring antibody
responses to parasite antigens. This holds the promise that a
single sample could add substantially more information to
population-level measures of transmission because each anti-
body response measured provides information about past ex-
posure in addition to current infection status. Obtaining antibody
data is quite practical: enzyme-linked immunosorbent assay
(ELISA) and some multiplexed assays are inexpensive and can
beperformedonmaterial extracted fromdriedbloodspotswhich
are simple to collect and transport; point-of-contact tests such
as lateralflowandmicrofluidicassaysarealsooptions.The result
promises to be a more resolved picture of malaria transmission.
USING ANTIBODIES TO SHARPEN SURVEILLANCE DATA
There is growing interest in using serosurveys to gain un-
derstanding of disease transmission and inform control
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interventions across a broad set of pathogens.5 Antibodies
have been used to estimate exposure to pathogens, including
malaria parasites for over 70 years, but the approach has
become more accessible and standardized because of
availability of purified recombinant antigens and development
of appropriate analytical methods. A commonly used strategy
to estimate transmission intensity from serological surveys
has been used to analyze seropositivity by age to compute a
force of infection or seroconversion rate (SCR), which takes
advantage of the fact that individuals in more highly endemic
areas are more likely to have been exposed to malaria para-
sites and thus to have detectable antibody responses. These
methods were initially developed for permanently immunizing
infections such as measles and yellow fever,6,7 but adapted
for malaria in the last decade.8,9 By translating age-stratified
antibody prevalence data into a metric which reflects overall
transmission in a community, the SCR extracts meaningful
population information from individuals’ binary, typically long-
lived responses to immunogenic Plasmodium proteins
(Figure 1A). This strategy has been validated across a wide
FIGURE 1. Established and next-generation methods for evaluating malaria transmission via antibodies provide higher resolution than parasite
prevalence. (A) The seroconversion rate (SCR) for a population can be calculated fromage-stratified prevalence of antibody responses, oftenwith a
long half-life. Data shown here are responses to apical membrane antigen 1 from three cross-sectional surveys in Uganda.34 (B) Paired SCR and
parasite rate (PR) data from multiple sites10,34–43 demonstrate that SCR (using merozoite surface protein 1, MSP-1) has a tighter association with
transmission, as measured by the annual entomologic inoculation rate (EIR). (C) Using six antibodies identified as informative about recent
exposure, predictions ofP. falciparum exposure in a community can be obtained from relatively small surveys, in contrast to PR data obtained from
the same surveys.19 (D) A simulation of a small village (N = 100) with seasonal, low transmission illustrates how ongoing transmission can be
detected consistently from an antibody test measuring recent exposure, but less reliably from rapid diagnostic test (RDT).44 This figure appears in
color at www.ajtmh.org.
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range of epidemiologic settings, and clearly demonstrates the
value of collecting antibody data in surveys (Figure 1B).
The SCR provides a useful metric for stable, community-
level transmission, but with recent successes in decreasing
malaria transmission, it is frequently of interest to measure
changes in exposure over time. Signals of abrupt changes in
exposure have been detected in the age-stratified antibody
prevalence profile by estimating a change in SCR, reflecting a
change transmission intensity at some point in time or with a
certain age.10 However, it is difficult to quantify very recent
changes in exposure from binary antibody responses with a
long half-life.11 Similarly, it is often difficult to quantify changes
in transmission from samples collected at a single time point
as they may be confounded by age dependence in risk. For-
tunately, the humanantibody response to complex pathogens
contains rich information which can be leveraged if the right
responses are identified, measured, and analyzed appropri-
ately. Advances are beingmade in three related areas: 1) using
information contained in the titers of antibodies, instead of
reducing them to binary responses; 2) measuring antibodies
to multiple antigens with differing kinetics, rather than limiting
measurement to oneor a few antigenswith long half-lives; and
3) developing analytical methods which take advantage of
these rich data to provide precise, quantitative estimates of
exposure history in populations from more intensive analysis
of fewer samples.
Methods have been recently developed to extend the
analysis of age-stratified antibody prevalence by in-
corporating antibody titers.12–14 Some of these models are
similar in concept to those used to calculate SCR, but allow
for different rates of boost and decay of relative antibody
concentrations—data which are often already available
from standardized ELISA or multiplex assay readouts. By
using more information, these methods should produce
more precise estimates of malaria transmission than those
derived from binary responses. In parallel, investigators
have begun to evaluatewhat information can be obtained by
measuring responses to different antigens.15–18 Not sur-
prisingly, responses to different antigens appear to provide
information of greater or lesser value for answering specific
epidemiologic questions in different populations depending
on their immunogenicity and other properties. For example,
by evaluating SCR to hundreds of proteins using a protein
microarray, Baum et al.15 showed that a distinct subset of
these targets was more efficient in distinguishing trans-
mission in two areas of highland Kenya. Similarly, Ondigo
et al.16 demonstrated that seroconversion and reversion
rates to different antigens varied considerably and illus-
trated how evaluating SCR to a number of antigens could
provide more information on the temporal structure of past
exposure than looking at responses to a single antigen. To
turn these promising findings into reliable, informative an-
tibody assays, we propose a strategy to design Combined
Antibodies to Measure Exposure Recency Assays (CAMERAs)
with the aim of answering actionable questions across a range
of epidemiologic settings.19
DESIGNING HIGH-RESOLUTION CAMERAS FOR
ACTIONABLE MALARIA SURVEILLANCE
Obtaining precision surveillance data from antibodies re-
quires a detailed understanding of how antibody responses
change over time in response to infection, and how these ki-
netics aremodulated by factors such as age, genetic diversity
in parasite and host, and prior Plasmodium exposure (in-
cluding different species). Initiating prospective studies to
define antibody kinetics throughout a representative set of
epidemiologic settings would be an enormous endeavor.
Fortunately, a number of well-characterized cohorts have
been performed or are ongoing inmalaria-endemic areas, and
many have archived appropriate biologic material in the form
of serum, plasma, or dried blood spots.20–28 The most useful
of these have detailed capture of malaria infections through
frequent active (e.g., monthly) and continuous passive sur-
veillance, follow participants for an extended period of time
(ideally ³ 1 year), and have sufficient sample sizes to capture
individual heterogeneity (e.g., ³ 50 per age strata). Cohorts in
which a documented change in transmission intensity has
occurred are of particular interest, as these offer the best
opportunity to disentangle recent from cumulative exposure.
With these existing studies providing at least a subset of the
samples needed, the next step is to identify antibody re-
sponses that are most informative about transmission. Al-
though it has been shown that different antigens tend to elicit
different qualities of response,29,30 it is still difficult to predict
these a priori. In addition, it is not just the average of any
particular metric of response to an antigen (e.g., degree of
boosting with exposure, and half-life) that matters but also
biological variation in these qualities across individuals.
Therefore, a broad screen of responses provides the highest
probability of identifying the optimal set of informative
biomarkers.
High-throughput screens using protein microarrays or
similar technologies offer one such approach.18,31 This tech-
nique allows rapid screening of a large number of responses
and requires minimal amounts of both sample and antigen.
Rapid production of “crude” antigens without much optimi-
zation allows a large number of antibody responses to be
screened up front with minimal start-up time. One potential
downside of this approach is that a subset of antigensmay not
be properly expressed or folded, but this potential limitation is
less of an issue for efforts trying to identify markers of expo-
sure as opposed to characterizing correlates of immunity.
Furthermore, this downside is potentially overcome by sheer
numbers—responses to certain sets of antigens are likely to
provide similar information, and by screening many analytes
simultaneously, it is likely that at least one representative
member of each setwill be successfully evaluated.Other high-
throughput approaches, includingpeptide arrays32 andphage
display libraries,33 may allow rapid evaluation of individual
linear epitopes, including the ability to capture naturally oc-
curring genetic variation in the target. The effort in producing
standardized reagents at scale—ultimately required for final
assays—can then be focused on a down selected set of
promising antigens followed by iterations of validation to de-
sign CAMERAs (Figure 2).
We have recently demonstrated the feasibility and potential
of this approach, screening plasma samples from two cohorts
of children in Uganda using a protein microarray containing
856 Plasmodium falciparum antigens, included based on their
potential to provide information about prior exposure to this
parasite.19 In this study, data froma small subset of antibodies
(e.g., 3–6) chosen based on their combined information con-
tent measured at a single time point provided accurate
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estimates of whether an individual was infected in the last 30,
90, or 365 days and on their incidence of malaria in the prior
year. These quantitative, individual-level data rivaled the rich
information obtained from expensive cohort studies. For ex-
ample, estimates of incidence obtained from antibodies ac-
curately reproduced the spatial heterogeneity in transmission
within a community detected by 1 year of entomological and
clinical cohort data. When aggregated, antibody data from
individuals dramatically outperformed parasite prevalence in
precision and dynamic range, providing estimates of the in-
cidence of malaria in a community from sample sizes as small
as 20 (Figure 1C).
The specific antibody responses selected to be measured
will dependonwhicharemost informative for agiven scenario.
The number of potential antigens encoded by Plasmodium
genomes, and number of sequence variants for those under
balancing selection, is large, providing an embarrassment of
riches regarding what to measure. Antibodies directed at an-
tigensexpressedexclusivelyduring thepre-erythrocytic stage
of infection may make good markers of newly acquired in-
fection; those continually boosted by low-density asexual-
stage infection may be better indicators of recent chronic
infection; those specific for a given plasmodia will provide
species-specific data. Evaluating responses to a panel of
antigenic variants, or evenspecificepitopeswithin thesevariants,
lookingatdifferent classesor immunoglobulinG (IgG) subclasses
of antibodies, and evaluating avidity may all in theory provide
additional information given the different kinetics of these
responses. Antibodies directed against mosquito salivary
antigens may provide additional information regarding ex-
posure to important vectors. In the end, consistent empiric
data validated acrossmultiple settings with appropriate gold
standards will be the best arbiter of what should be included
in a CAMERA. A number of platforms are currently available
formeasuring antibodies (Figure 2), and optionswill continue
to grow. Important factors informing appropriate platforms
include the number and type of antibody responses and
whether binary, semi-quantitative, or quantitative responses
are required; cost, portability, speed, and level of training and
equipment needed to perform the assay.
With the availability of samples and data from cohorts,
methods for high-throughput screeningof antibody responses,
and a robust data analysis approach considering combina-
tions of responses with appropriate validation, it should be
possible to craft antibody assays that will provide accurate
answers to nearly any malaria surveillance question with re-
spect to the rate and timing of human Plasmodium infection.
With that in mind, the most pressing questions will largely
depend on the epidemiologic setting and consumer of the
data (Table 1). In areas of endemic transmission, it will be
important to measure variations in transmission over space
and time, especially in response to interventions. For these
settings, antibody assays will add power to surveys of par-
asite prevalence by increasing the range of transmission
FIGURE 2. Approach to designing combined antibodies to measure exposure recency assays (CAMERAs). (A) Samples from detailed cohorts,
where accurate data on individuals’ prior malaria infections are available, are critical for providing a gold standard to identify informative antibody
responses. Cohorts should represent the range of ages and epidemiologic settings where CAMERAswill ultimately be used. Various platforms are
available for high-throughput screening of antibody responses, with tradeoffs based on cost, number of analytes that can be screened, precision,
and dynamic range. (B) Down selection of the most informative combinations of responses (i.e., considered jointly) is accomplished via parametric
modeling of antibody kinetics45 and/or any number of machine learning prediction algorithms. Both of these analytical approaches have advan-
tages, and combining bothmay be optimal. (C) Top “hits” identified in comprehensive screens require validation in distinct individuals and cohorts.
Given the smaller number of responses evaluated, it may be feasible to evaluate much larger numbers of samples including longitudinal sampling
from individuals over time. (D) Final CAMERAs can be designed as point-of-contact (e.g., based on lateral flowormicrofluidics) or laboratory-based
assays, depending on the use case. The analytics for deriving epidemiologically relevant metrics from antibody responses will be integral to the
assay. This figure appears in color at www.ajtmh.org.
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intensities over which estimates can be accurately obtained,
and by increasing precision, allowing for smaller sample
sizes and/or spatial mapping at a more granular level. In
settings where P. vivax is endemic, a serologic test of recent
infection may signal the presence of hypnozoites and thus
need for radical cure. For control programs deciding strategy
in areas of very low transmission attempting to eliminate
malaria, additional questions become important. In such
areas, it is of interest to identify all individuals who have been
infected within a defined period of time to understand if local
transmission is occurring, and if so where, how much, and in
whom. In these areas, data on recent infections are of par-
ticular added value, given the large sample sizes otherwise
needed toconfirmorexcludeongoing transmission (Figure1D).
Evidence of more remote infection may also be of interest, to
provide historical context for transmission potential when
transmission has been interrupted. Finally, in the research
setting, biomarkers of individuals’ prior malaria exposure may
be important outcomes in epidemiologic studies, or as ways to
adjust analyses for heterogeneous exposure, for example,
when investigating mechanisms of immunologic protection.
PEOPLE ARE DIFFERENT, AND THAT IS OK
The extent towhich particular surveillance questions can be
answered by antibody data, and the corresponding sample
sizes required to obtain answers with a given accuracy, will be
largely determined by the sources of variation in antibody re-
sponses and the degree to which this variability can be sys-
tematically accounted for. Although laboratory methods can
be optimized to minimize technical variation in the measure-
ment of titer or presence versus absence of an antibody re-
sponse, biological variationwill remain. Someof thisbiological
variationmaybeattributable to identifiable factors suchasage
and history of prior infection, but some will be unmeasured
biological variability that is difficult to account for, for example,
due to host genetics or nutritional status. In addition, differ-
ences in the sequence of parasite antigens, if not adequately
TABLE 1
Actionable malaria surveillance data obtainable with combined antibodies to measure exposure recency assays
Setting Relevant questions Information derived from antibody assays Added value to traditional metrics
Programmatic,
endemic
What is the current level of
transmission and how does it vary
over space and time?
Accurate estimates of transmission
intensity calibrated to relevant
metrics (e.g., force of infection) now
and over time for communities. In
particular, how intensity changes in
response to interventions, human
and mosquito behavior, and other
factors.
Dynamic range allows estimates over
a broader range of transmission
intensity than parasite prevalence.
Where are interventions most needed
and which are optimal?
Estimates of recent Plasmodium vivax
infection, and thus likely hypnozoite
carriage.
Increased precision allows for smaller
sample sizes and/or spatial
mapping at a more granular level.
How well are current interventions
working?
– Ability to measure prior and current
transmission, for areas where prior
estimates are not available.
Are individuals infected with dormant
stages of parasites (P. vivax)?
– Ability to determine whether
individuals are latently infected with
P. vivax.
Programmatic,
peri-elimination
(above plus) Where recently or currently infected
individuals live.
(above plus)
Where are residual foci of
transmission, if any?
Identification of parasite species
causing recent infections.
More information from each individual
allows for smaller sample sizes and/
or more granular spatial data.
Which Plasmodium species are
causing infections?
Demographics of recently or currently
infected individuals.
Increased sensitivity for detecting
infections when they are rare,
including by species such as
Plasmodium knowlesi, by detecting
over a larger range of time.
What are the demographic groups at
the highest risk of infection or
transmission to others?
How far in the past infections took
place.
Ability to reconstruct historical
exposure from contemporary
measurements.
Has transmission been interrupted? Historical spatial distribution of
malaria exposure.
Ability to measure waning immunity.
What is the receptivity of the area? Probability of individuals experiencing
symptomatic or severe disease on
infection.
–
Is the population susceptible to
epidemic transmission?
– –
Research What are the epidemiologic risk
factors for infection with malaria
parasites?
Estimates of individuals’ prior
exposure.
Ability to evaluate diversity of
parasites to which individuals have
been previously exposed, for
example, by measuring breadth of
responses to polymorphic antigens.
What are the biomarkers and
mechanisms of immunity to
malaria?
Determining how much variation in
naturally acquired immunity can be
attributed to differences in prior
exposure.
Ability to estimate individuals’
cumulative and recent exposure
before observation during the
research study.
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taken into consideration, can provide an additional source of
variation between individuals within a site or between geo-
graphic sites. Together, these sources of variation will set in-
herent limits on the precision of information that can be
obtained from a particular antibody response in a given per-
son. Despite this variation, precise population-level estimates
can be obtained from antibody responses by 1) measuring
responses tomultiple antigens; 2) samplingmultiple people in
a given area; 3) incorporating knowledge of age–exposure–
antibody relationships into data analysis; and 4) tailoring
antibody assays to specific age groups and/or transmission
intensities. Regarding the latter, although having a universal
antibody assay for use in all settings may seem the most
straightforward, in reality it is likely that certain sets of re-
sponses will have more utility in some settings versus others.
For example, antibody responses which provide information
about a decline in entomologic inoculation rate from 100 to 10
infectious bites per person year may be different than those
which can confirm the absence of recent exposure in an
elimination setting. Depending on multiplex capacity, the
same standardized laboratory platform may essentially con-
tainmultiple “assays,”ofwhich only a subset are actually used
to produce outputs for a given setting. Platforms requiring a
more parsimonious set of analytes, for example, standard
lateral flow assays may be best targeted to a specific epide-
miologic setting.
The apparent ambiguity of how to interpret a particular an-
tibody response in a particular individual has been a psycho-
logical barrier in thewidespread dissemination andacceptance
of antibody data for surveillance. However, more commonly
used metrics, such as parasite prevalence, are subject to
similar caveats. Detecting a parasite in an individual’s blood,
while seemingly concrete, is still an indirect measure of
transmission mediated by the duration and density of in-
fection, which are functions of age, prior exposure, and the
limit of detection of the assay used (e.g., microscopy versus
PCR). For this reason, parasite prevalence requires age
standardization a reasonably sized sample of the population
to obtain a single point estimate.3 Estimates of transmission
derived from antibodies will also be averaged across a
population sample. Thus, while there will be some un-
certainty as to, for example, if a particular individual has been
infected two versus three times in the past year, precise es-
timates of transmission can still bederived for the population.
As discussed earlier, the increased granularity of information
provided by antibody data for each individual will likely result
in more accurate estimates from smaller sample sizes de-
spite inherent biological variation. This advantage holds
across all transmission intensities but may be particularly
salient in areas of very low transmission.
PRACTICAL CONSIDERATIONS FOR INCORPORATING
CAMERAS INTO ROUTINE SURVEILLANCE
Antibody measurements have great potential for aug-
menting information obtained in malaria surveillance activi-
ties. However, specific questions remain on what should be
measured, in whom, and how to best make sense of the data
(Figure 3). This will inevitably be an iterative process, with
analytes, platforms, and analytical methods building on prior
efforts. If methods are designed to map to relevant metrics of
interest, for example, force of infection in the last year or the
presence or absence of infection within the past year, then
methods with improved test characteristics can be imple-
mented as they become available with comparable outputs.
Once CAMERAs are designed and test characteristics are
known, for example, among which age groups they are in-
formative in a given setting, appropriate surveillance activities
for sample collection and antibody measurement can be de-
termined. For cross-sectional surveys, for example, malaria
indicator surveys, school surveys, active and reactive case
detection, and other surveillance activities, including those
performed in intervention trials, CAMERAs offer a clear oppor-
tunity for obtaining additional information. Suchmeasurements
will add little incremental cost and, in fact, may offer substantial
cost savings as smaller sample sizesmay be required to obtain
similar information. Incorporatingmeasurement of antibodies in
many cases requires no additional field work because many
such surveys are already collecting dried blood spot samples.
For example, demographic and health surveys (DHS) con-
ducted in more than 50 countries already collect serum sam-
ples to measure specific biomarkers.5 Efficient collection of
samples fromother convenientvenues, for example, fromthose
presenting to health facilities for routine care may provide
FIGURE 3. Outstanding questions for developing and using combined antibodies to measure exposure recency assays (CAMERAs).
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continuous, low-cost data to augment metrics such as test
positivity rates and malaria incidence. The ease of collecting
more comprehensive data at low cost via such approaches will
need to be balancedwith issues surrounding potentially biased
sampling and is an area ripe for further investigation.
Finally, antibody data generated need to be consistently
translated into easily interpretable metrics of transmission. De-
velopment and evaluation of analytical methods will be an in-
tegral part of assay design, critical for making decisions
regarding the number and type of antibody responses which
will be measured. Simple point-of-care assays may require
straightforward interpretation, for example, a band visible on a
lateral flow assay might indicate infection within the past year.
However, given the potential increase in the breadth and accu-
racy of information obtained from combining data from multiple
antibody responses, other assays may use more sophisticated
algorithms. Such algorithms can be easily implemented in soft-
ware to provide straightforward interpretation regardless of the
complexity of the underlying algorithm.
The path for developing high-resolution CAMERAs is clear,
and a number of research teams are working toward an-
swering thesalientquestionsoutlinedpreviously.AsCAMERAs
are designed, validated, and improved, their key role in malaria
surveillance will come into clear focus.
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